ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, has announced that Dr. Daljeet Singh Gambhir, Director of Cardiology and Chief Executive Officer of the Kailash Heart Institute, has been appointed to the Company’s Medical Advisory Board and will hold the position of Clinical Advisor to MIVT India.
